IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

: U.S. Serial Number 10/541,388

Applicant

: Rappold-Hoerbrand et al.

Filed

: July 1, 2005

TC/A.U.

Examiner

Docket No. Customer No. : 2851-140

: 6449

Confirmation No.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants submit herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449. The references are cited in the specification. Copies of the references are attached.

This statement is being submitted prior the receipt of the first Office Action on the merits. No certification or fee is required.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

Monica Chin Kitts

Reg. No.: 36,105

Attorney for Applicants Registration No. 22,980

ROTHWELL, FIGG, ERNST & MANBECK, PC

1425 K. Street, Suite 800 Washington, D.C. 20005

Telephone: (202) 783-6040

					Complete if Kn	nown		
					Application Number	10/541,388		
INFORMATION DISCLOSURE				RE	Filing Date	July 1, 2005	nd et al.	
STAT	STATEMENT BY APPLICANT		First Named Inventor Rappold-Hoerbran	Rappold-Hoerbrand et al.				
					Group Art Unit			
					Examiner Name			
					Confirmation No.			
Sheet		1	of	2	Attorney Docket Number	2951-140		

NON PATENT LITERATURE DOCUMENTS

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	1.	Bettencourt, "Brain Natriuretic Peptide (Nesiritide) in the Treatment of Heart Failure," Cardiovascular Drug Reviews, Vol. 20, No. 1, (2002), pp. 27 – 36.			
	2.	Blaschke and Rappold, "SHOX: Growth, Léri-Weill and Turner Syndromes," TEM, Vol. 11, No. 6 (2000), pp. 227-230.			
	3.	Bordenave et al., "Human bone marrow endothelial cells: a new identified source of B-type natriuretic peptide," Peptides 23 (2002), pp. 935-940.			
	4.	Burger M. R., Burger A. J. (2001) BNP in decompensated heart failure: diagnostic, prognostic and therapeutic po tential. Curr. Opin. Investig. Drugs, 2(7): 929-935.(Abstract)			
	5.	Carel et al., "Near Normalization of Final Height with Adapted Doses of Growth Hormone in Turner's Syndrome," <u>J. Clinical Endocrinology & Metabolism</u> , Vol. 83, No. 5 (1998), pp. 1462-1466.			
	6.	Cho, Y., Somer, B. G. and Amatya A. (1999) Natriure:tic peptides and their therapeutic potential. Heart Dis. Nov-Dec; 1 (5): 305-328. (Abstract)			
	7.	Chusho et al., "Genetic Models Reveal That Brain Natriuretic Peptide Can Signal through Different Tissue-Specific Receptor-Mediated Pathways*," <u>Endocrinology</u> , Vol. 141, No. 10 (2000), pp. 3807-3813.			
	8.	Chusho et al., "Dwarfism and early death in mice lacking C-type natriuretic peptide," PNAS, Vol. 98, No. 7 (March 2001), pp. 4016-4021.			
	9.	Dhingra et al., "Brain Natriuretic Peptide: Role in Cardiovascular and Volume Homeostasis," Seminars In Nephrology , Vol. 22, No. 5 (September 2002), pp. 423-437.			
	10.	Ellison et al., "PHOG, a candidate gene for involvement in the short stature of Turner syndrome," <u>Human Molecular Genetics</u> , Vol. 6, No. 8 (1997), pp. 1341-1347.			
	11.	Ogawa, Y., Itoh,H., Nakagawa,O., Shirakami,G., Tamura,N., Yoshimasa, T., Nagata,K., Yoshida,N. and Nakao,K. (1995) Characterization of the 5'-flanking region and chromosomal assignment of the human brain natriuretic peptide gene. J. Mol. Med.1995 Sep; 73 (9): 457-463. (Abstract)			
	12.	Rappold et al., "Deletions of the Homeobox Gene SHOX (Short Stature Homeobox) Are an Important Cause of Growth Failure in Children with Short Stature," J. Clinical Endocrinology & Metabolism, 87(3) (March 2002), pp. 1402-1406.			
	13.	Rao et al., "Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome," Nature Genetics, Vol. 16, (May 1997), pp. 54-63.			

				Complete if Known	
INFORMATION DISCLOSURE				Application Number	10/541,388
				Filing Date	July 1, 2005
STATEN	STATEMENT BY APPLICANT			First Named Inventor	Rappold-Hoerbrand et al.
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	2	of	2	Attorney Docket Number	2951-140

NON PATENT LITERATURE DOCUMENTS

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	14.	Rao et al., "The Leri-Weill and Turner syndrome homeobox gene SHOX encodes a cell-type specific transcriptional activator", HUMAN MOLECULAR GENETICS, 2001, vol. 10, no. 26, 3083-3091.	
	15.	Rosenfeld et al., "Recommendations for Diagnosis, Treatment, and Management of Individuals with Turner Syndrome," <u>Endocrinologist</u> , Vol. 4, No. 5 (1994), pp. 351-358.	
	16.	Rosenfeld, et al., "Growth hormone therapy of Turner's syndrome: Beneficial effect on adult height," <u>J. of Pediatrics</u> , Vol. 132, No. 2 (Feb. 1988), pp. 319-324.	
	18.	Sas et al., "Normalization of Height in Girls with Turner Syndrome after Long-Term Growth Hormone Treatment: Results of a Randomized Dose-Response Trial*," <u>J. Clinical Endocrinology & Metabolism</u> ," Vol. 84, No. 12 (1999), pp. 4607-4612.	
	19	Seilhamer, J.J., Arfsten, A., Miller, J.A., Lundquist, P., Scarborough, R.M., Lewicki, J.A. and Porter, J.G. (1989) Human and canine gene homologs of porcine brain natriuretic peptide. Biochem. Biophys. Res. Commun. 1989 Dec 15; 165(2); 650-8. (Abstract)	
	20.	Suda et al., "Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide," Proc. Natl. Acad. Sci.USA, Vol. 95 (1998), pp. 2337-2342.	
	21.	Weinmann and Farnham, "Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation," Methods 26 (2002), pp. 37-47.	
	22.	Wilson, D., Sheng, G., Lecuit, T., Dostatni, N. and Desplan, C. (1993) Cooperative dimerization of paired class homeodomains on DNA. Genes & Dev., Vol. 7, 2120-2134. (Abstract)	
	23.	Wilson, D. S., Guenther, B., Desplan, C. and Kuriyan, J. (1995) High resolution crystal structure of a paired (pax) class cooperative homeodomain dimer on DNA. Cell, 82: 709-719.	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached. *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.